Form 4: Regeneron Executive Reports Future Stock Transactions

Regeneron's Co-Chair, President & CSO George Yancopoulos, reported the future vesting of performance stock units and subsequent sale of shares for tax purposes, scheduled for December 31, 2025.

Summary

• George Yancopoulos, Board Co-Chair, President & CSO of Regeneron Pharmaceuticals, Inc. (REGN), filed a Form 4 detailing future transactions under a Rule 10b5-1 plan.
• On December 31, 2025, Mr. Yancopoulos is scheduled to acquire 28,570 shares of Common Stock at a price of $0.0, resulting from the vesting of 2020 Performance Stock Units (PSUs).
• Concurrently, on December 31, 2025, he is scheduled to dispose of 28,570 shares of Common Stock at a price of $772.09, likely to cover tax obligations related to the PSU vesting.
• Following these transactions, Mr. Yancopoulos will directly own 310,460 shares of Common Stock and indirectly own 615,485 shares through various trusts and plans.
• He will also beneficially own 595,077 derivative securities in the form of 2020 Performance Stock Units.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-planned insider transactions related to executive compensation and tax obligations, which are neutral in terms of market sentiment.

Positives

• The vesting of 28,570 Performance Stock Units indicates the achievement of performance targets over the applicable five-year period, reflecting positively on executive performance.
• The transactions are pre-planned under a Rule 10b5-1(c) plan, demonstrating structured and compliant insider trading practices.

Negatives

• The disposition of 28,570 shares, even for tax purposes, reduces the direct beneficial ownership of the executive in the company's common stock.

Future Outlook

The filing details future transactions scheduled for December 31, 2025, related to executive compensation and tax obligations, indicating a pre-planned execution of a Rule 10b5-1 plan.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies, particularly in the pharmaceutical sector where long-term incentive plans like PSUs are prevalent.

Stakeholder Impact

• Shareholders: The transactions are routine and pre-planned, reflecting standard executive compensation practices and are unlikely to have a significant direct impact on shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The vested PSUs remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.

Key Dates

Keywords

Regeneron, REGN, Form 4, Insider Transaction, Executive Compensation, Performance Stock Units, Stock Vesting, Rule 10b5-1, George Yancopoulos